Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02168725 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
A Phase 1 study, sponsored by Traws Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02168725: Clinical Trial Phase 1 study, sponsored by Traws Pharma.
NCT02168725 is a Phase 1 study that was terminated before completion, run by Traws Pharma. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02168725, a Phase 1 study, was terminated before completion, sponsored by Traws Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The main objectives of this study are to determine the safety profile of briciclib, an experimental anti-cancer drug, as it is administered intravenously once weekly as escalating doses in adult patients with advanced cancer and solid tumors, and to determine the highest dose of briciclib that can be safely given. Secondary objectives are to determine how the amount of briciclib in circulation changes over time and how much briciclib gets into the urine for excretion, and to document potential anti-tumor effects of briciclib.
Primary Outcome
Adverse events will be grouped by system organ class (SOC) and preferred term (PT) using the most recent version of the Medical Dictionary for Regulatory Activities (MedDRA), and will be summarized by worst grade according to NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
Interventions
- DRUG briciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Why NCT02168725 stopped before completion
NCT02168725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which briciclib is the first listed.
NCT02168725 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02168725 about?
NCT02168725 is a clinical study titled "Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors". The main objectives of this study are to determine the safety profile of briciclib, an experimental anti-cancer drug, as it is administered intravenously once weekly as escalating doses in adult patients with advanced cancer and solid tumors, and to determine the highest dose of briciclib that can b...
What is the current status of trial NCT02168725?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02168725?
The interventions under investigation include: briciclib (DRUG).
Who is sponsoring clinical trial NCT02168725?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02168725's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia